Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Atle Fund Management AB

Q4 2023 · 13F-HR

Atle Fund Management ABholdings as filed

Filed 2024-01-30 · accession 0001381843-24-000002

$127.8M
Reported value
45
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
91324P102UNHUNITEDHEALTH GROUP INC$9.7M7.59%18,408CommonSOLE
532457108LLYELI LILLY & CO$9.2M7.21%15,805CommonSOLE
375558103GILDGILEAD SCIENCES INC$8.0M6.28%98,974CommonSOLE
03073E105CORCENCORA INC$8.0M6.26%38,925CommonSOLE
58933Y105MRKMERCK & CO INC$7.2M5.60%65,675CommonSOLE
883556102TMOTHERMO FISHER SCIENTIFIC INC$6.1M4.74%11,415CommonSOLE
14149Y108CAHCARDINAL HEALTH INC$4.8M3.79%48,000CommonSOLE
413197104HRMYHARMONY BIOSCIENCES HLDGS IN$4.7M3.67%145,000CommonSOLE
031162100AMGNAMGEN INC$4.6M3.61%16,023CommonSOLE
15135B101CNCCENTENE CORP DEL$4.6M3.60%62,000CommonSOLE
60855R100MOHMOLINA HEALTHCARE INC$4.5M3.54%12,500CommonSOLE
110122108BMYBRISTOL-MYERS SQUIBB CO$4.5M3.53%88,000CommonSOLE
125523100CITHE CIGNA GROUP$4.5M3.52%15,000CommonSOLE
036752103ELVELEVANCE HEALTH INC$4.5M3.51%9,500CommonSOLE
863667101SYKSTRYKER CORPORATION$3.8M3.00%12,802CommonSOLE
101137107BSXBOSTON SCIENTIFIC CORP$3.7M2.93%64,806CommonSOLE
92532F100VRTXVERTEX PHARMACEUTICALS INC$3.7M2.91%9,130CommonSOLE
75886F107REGNREGENERON PHARMACEUTICALS$3.5M2.74%3,979CommonSOLE
00287Y109ABBVABBVIE INC$3.3M2.57%21,196CommonSOLE
46266C105IQVIQVIA HLDGS INC$2.4M1.87%10,340CommonSOLE
252131107DXCMDEXCOM INC$2.2M1.75%18,057CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$1.7M1.30%12,617CommonSOLE
28176E108EWEDWARDS LIFESCIENCES CORP$1.6M1.24%20,815CommonSOLE
68404L201OPCHOPTION CARE HEALTH INC$1.3M0.98%37,223CommonSOLE
717081103PFEPFIZER INC$1.2M0.96%42,820CommonSOLE
462222100IONSIONIS PHARMACEUTICALS INC$1.2M0.96%24,243CommonSOLE
36118A100FUSION PHARMACEUTICALS INC$1.2M0.94%125,000CommonSOLE
23282W605CYTKCYTOKINETICS INC$979,5880.77%11,733CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$968,2740.76%23,985CommonSOLE
30063P105EXKEXACT SCIENCES CORP$899,3750.70%12,157CommonSOLE
46116X101ITCIEURINTRA-CELLULAR THERAPIES INC$876,9870.69%12,245CommonSOLE
641871108AMBRX BIOPHARMA INC$823,7410.64%57,847CommonSOLE
501147102KRYSKRYSTAL BIOTECH INC$821,7730.64%6,624CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$691,1950.54%48,710CommonSOLE
82489T104SWAVUSDSHOCKWAVE MED INC$672,6770.53%3,530CommonSOLE
N5749R1002GHMERUS N V$668,9380.52%24,325CommonSOLE
457730109INSPINSPIRE MED SYS INC$656,8750.51%3,229CommonSOLE
03940C100ACLXGBXARCELLX INC$632,7000.50%11,400CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$620,4620.49%96,345CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$585,6230.46%2,531CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$534,4670.42%7,823CommonSOLE
12674W109CABACABALETTA BIO INC$476,7000.37%21,000CommonSOLE
61775R105MORFUSDMORPHIC HLDG INC$431,8140.34%14,952CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$360,3370.28%15,432CommonSOLE
G72800108PRTAPROTHENA CORP PLC$303,1480.24%8,342CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.